Maynard Um
-
-
-
-
-
-
-
Oppenheimer Starts Aclaris Therapeutis (ACRS) at Outperform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)
-
-
-
-
-
-
-
Aclaris reports positive Phase 2a results for atopic dermatitis drug
-
-
-
-
-
-
-
Aclaris Therapeutics (ACRS) Gains ~20% Following Wedbush Coverage Launch
-
-
-
-
-
-
-
Aclaris Therapeutics (ACRS) reported Q4 Revenue
-
-
-
-
-
-
-
Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session
-
-
-
-
-
-
-
Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel
-
433,621 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

